Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 309

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 309
---
 do not have insurance coverage to compensate us for such business interruptions. Our contract manufacturers and suppliers
provide that in their separate operations; however, such coverage may prove insufficient to fully compensate us for the damage to our
business resulting from any significant property or casualty loss to those facilities.

We
have significant and increasing liquidity needs and may require additional funding.

Our
operations have consumed substantial amounts of cash since inception. For the year ended December 31, 2024, we reported a net operating
cash outflow of $5.1 million and a net cash inflow from financing activities of $6.3 million. For the year ended December 31, 2023, we
reported a net operating cash outflow of $3.9 million and a net cash inflow from financing activities of $3.9 million.

Research
and development, and general and administrative expenses, and cash used for operations will continue to be significant and may increase
substantially in the future in connection with new research and development initiatives and continued product commercialization efforts.
We may need to raise additional capital to fund our operations, continue to conduct clinical trials to support potential regulatory approval
of marketing applications and to fund commercialization of our products.

28

The
amount and timing of our future funding requirements will depend on many factors, including, but not limited to:

    ●
    the
    timing of FDA approval, if any, and approvals in international markets of our product candidates, if at all; 

    ●
    the
    timing and amount of revenue from sales of our products, or revenue from grants or other sources;

    ●
    The
    rate of progress and cost of our clinical trials and other product development programs; 

    ●
    costs
    of establishing or outsourcing sales, marketing, and distribution capabilities; 

    ●
    costs
    and timing of completion of expanded in-house manufacturing facilities as well as any outsourced commercial manufacturing supply
    arrangements for our product candidates; 

    ●
    costs
    of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights associated with our product
    candidates; 

    ●
    the
    effect of competing technological and market developments; 

    ●
    personnel,
    facilities, and equipment requirements; and 

    ●
    the
    terms and timing of any additional collaborative, licensing, co-promotion, or other arrangements that we may establish.

While
we expect to fund our future capital requirements from